European Medicines Agency Sustainability Profile
The European Medicines Agency (EMA), headquartered in the Netherlands, plays a pivotal role in the pharmaceutical industry by ensuring the safety and efficacy of medicines across Europe. Founded in 1995, the agency has been instrumental in the evaluation and supervision of medicinal products, facilitating access to innovative therapies for patients. With a focus on human and veterinary medicines, the EMA collaborates with national regulatory authorities to uphold high standards in public health. Its unique position allows for streamlined processes in drug approval, making it a cornerstone of the European healthcare landscape. Notable achievements include the rapid assessment of COVID-19 vaccines, showcasing its agility in responding to public health emergencies. The EMA continues to lead in regulatory science, fostering innovation while safeguarding patient safety.
DitchCarbon Score
How does European Medicines Agency's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
European Medicines Agency's score of 30 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
European Medicines Agency's reported carbon emissions
In 2023, the European Medicines Agency (EMA) reported total carbon emissions of approximately 1,901,900 kg CO2e, with all emissions classified under Scope 3, specifically from business travel, which accounted for about 1,682,900 kg CO2e. This marks a significant increase from 2022, when total emissions were approximately 979,900 kg CO2e, with business travel contributing about 791,600 kg CO2e. The EMA's emissions data for previous years shows a consistent focus on business travel as the primary source of their carbon footprint, with 2021 emissions at about 178,500 kg CO2e and 2020 emissions at approximately 809,100 kg CO2e. Notably, the agency has not disclosed any Scope 1 or Scope 2 emissions data. Despite the increase in emissions, the EMA has not set specific reduction targets or initiatives, nor have they committed to any climate pledges or SBTi targets. This lack of formal commitments may reflect the agency's current focus on operational activities rather than comprehensive climate strategies. Overall, the EMA's emissions profile highlights the importance of addressing business travel emissions as part of their climate impact, while also indicating a need for clearer climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | 525,700 | 000 | 000,000 | 0,000,000 |
How Carbon Intensive is European Medicines Agency's Industry?
How Carbon Intensive is European Medicines Agency's Location?
European Medicines Agency's Scope 3 Categories Breakdown
European Medicines Agency's Scope 3 emissions, which increased by 113% last year and increased by approximately 220% since 2020, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Business Travel" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
European Medicines Agency's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
European Medicines Agency has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
